Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paion has acquired the world-wide rights to flovagatran, a direct thrombin inhibitor, from UK-based Trigen for an upfront payment of approximately E0.3 million.
Subscribe to our email newsletter
Paion will be required to make a milestone payment in the event flovagatran receives regulatory approval or is licensed or sold in a major market but will not be required to pay ongoing royalties.
Flovagatran is a chemically synthesized anticoagulant for intravenous administration. It directly blocks the activity of thrombin, thereby preventing the formation of blood clots. The substance has been tested in two small Phase IIa clinical trials for dialysis and percutaneous transluminal coronary angioplasty, which is one of the most common procedures for opening damaged or obstructed coronary arteries.
Wolfgang Sohngen, CEO of Paion, said: “We believe that it has potential as an anticoagulant for use in a variety of hospital-based interventions. As an initial step, we intend to conduct additional preclinical studies, on the basis of which we will formulate a clinical development strategy for flovagatran.”